Novo Stock (NVO) Falls After Another Head-to-Head Obesity Trial Loss to Eli Lilly
Shares of Danish pharma giant Novo ($NVO) edged lower to around $38 on Wednesday afternoon. This came after rival drugmaker Eli Lilly ($LLY) announ...
Novo Nordisk A S (NVO)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Markel Gayner Asset Management Tom Gayner | 2,869,774 | $108,793,131 | 0.85% | |
| 2. | Bailard Inc Thomas Bailard | 7,461 | $282,847 | +1% | 0.01% |
| 3. | 0 | $0 | 0% | ||
| 4. | Laurion Capital Management Benjamin A. Smith | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,468,494 | $245,220,608 | 2.9% | |
| 2. | 3,181,453 | $120,608,883 | 6.64% | |
| 3. | 833,519 | $31,598,705 | 0.33% | |
| 4. | 593,191 | $27,209,442 | 2.23% | |
| 5. | 699,121 | $26,503,683 | 0.03% |
News See All
Wall Street Has High Expectations for Eli Lilly Stock (LLY) Heading into Earnings
The company report earnings on Oct. 29.
Novo Nordisk Stock (NVO) Climbs 2% Today on Positive CagriSema Weight-Loss Data
Novo Nordisk stock gained on Tuesday alongside new weight-loss data from women who used CagriSema.
Eli Lilly Stock (LLY) Hits All-Time High Ahead of Earnings
The pharma giant reports financial results on Oct. 29.
Novo Nordisk’s Growth Story Is Under Pressure as Eli Lilly Gains Ground
Novo Nordisk S/A (NYSE:NVO)'s investment story has changed dramatically. The stock has declined by over 25% since the start of 2026. The selloff has changed the stock's valuation.
Novo Nordisk (NVO) Raised Its Outlook, Then Aimed for Average Growth
Novo Nordisk (NYSE:NVO) did something this year that usually pleases investors: it raised its full-year outlook.
Eli Lilly and Novo Face New Pressure from WHO’s Childhood Obesity Guidelines
The World Health Organization (WHO) issued its first-ever guidelines on childhood and adolescent obesity on Wednesday. The guidelines discourage we...
AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?
AI startup BioinvestGPT predicted the failure of Novartis AG’s ($NVS) experimental muscular dystrophy drug months before a disappointing Phase 3 re...
Novo Nordisk (NVO) or Eli Lilly (LLY)? Jim Cramer Gives a Clear Response
During the October 1 lightning round of Mad Money, a caller said they owned both Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Company (NYSE:LLY).
Novo Looks Beyond GLP-1s as Competition Intensifies
In the past, Novo Nordisk A/S (NYSE:NVO) has been a dominant player in diabetes and obesity treatments, with Ozempic and Wegovy driving a significant portion of the company’s recent growth.
Hedge Fund Resource Center